Pacific Biosciences Of California (PACB) Change in Receivables (2010 - 2026)

Pacific Biosciences Of California's Change in Receivables history runs 17 years deep, the most recent figure standing at -$6.1 million for Q1 2026.

• In Q1 2026, Change in Receivables fell 247.97% year-over-year to -$6.1 million; the TTM figure through Mar 2026 stood at -$2.3 million (down 273.6% YoY), while the FY2025 annual figure was $7.9 million, up 187.16% from the prior year.
• Change in Receivables was -$6.1 million for Q1 2026 at Pacific Biosciences Of California, down from $4.8 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $10.8 million in Q1 2023 to a low of -$6.3 million in Q1 2024.
• Historically, Change in Receivables has averaged $300529.4 across 5 years, with a median of -$794000.0 in 2022.
• The sharpest annual moves came in 2022 and 2025: Change in Receivables tumbled 1445.76% in 2022, then surged 359.92% in 2025.
• A 5-year view of Change in Receivables shows it stood at -$4.0 million in 2022, then surged by 254.38% to $6.1 million in 2023, then sank by 130.33% to -$1.9 million in 2024, then jumped by 359.92% to $4.8 million in 2025, then plunged by 226.2% to -$6.1 million in 2026.
• The last three Change in Receivables figures came in at -$6.1 million (Q1 2026), $4.8 million (Q4 2025), and -$1.6 million (Q3 2025), per Business Quant data.